Get the latest crypto news, updates, and reports by subscribing to our free newsletter.
Giấy phép số 4978/GP-TTĐT do Sở Thông tin và Truyền thông Hà Nội cấp ngày 14 tháng 10 năm 2019 / Giấy phép SĐ, BS GP ICP số 2107/GP-TTĐT do Sở TTTT Hà Nội cấp ngày 13/7/2022.
© 2026 Index.vn
Riverfront living has long been positioned as a luxury offering. As open spaces become scarcer, owning a private riverside retreat is increasingly seen as a form of privilege—particularly in central urban areas where land for such developments is nearly exhausted. The Privé is currently among the few central riverfront residential…
AbbVie, spun off from Abbott Laboratories in 2013, has raised its quarterly dividend each year since becoming an independent, publicly traded company. The company has done so despite a major headwind: losing major patent exclusivity for its prior flagship drug, Humira.
AbbVie has been able to solidify its position through the launches of autoimmune treatment Skyrizi and inflammatory disease treatment Rinvoq. Together, these therapies have helped offset declining Humira sales, allowing AbbVie to remain a dividend growth stock for more than a dozen years.
As Humira’s impact on AbbVie’s bottom line declines, the company’s sales performance has been supported by growth in its newer portfolio. The article notes that forecasts anticipate continued expansion in Skyrizi and Rinvoq, alongside additional growth from other AbbVie product lines.
Forecasts cited in the article call for Skyrizi and Rinvoq—reported to have generated $31 billion in revenue in 2025—to reach around $50 billion by 2030.
Late last year, AbbVie announced a 5.5% increase to its quarterly dividend, raising it to $1.73 per share, or $6.92 per share annually. The current payout rate corresponds to a forward dividend yield of around 3.2%.
The article also points to earnings growth expectations that could support larger dividend increases over time, citing forecasts for earnings to rise by around 45.4% in 2026 and 10.8% in 2027.
On valuation, the stock is described as trading at around 17 times forward earnings. The article characterizes this as a valuation premium versus other pharmaceutical stocks, while suggesting it may be supported by AbbVie’s stronger growth prospects.
While AbbVie is not yet expected to reach “Dividend King” status—defined in the article as companies with over 50 consecutive years of dividend growth—the piece argues that the company could eventually have a path to that milestone. It notes that AbbVie was spun out of a Dividend King in Abbott and highlights the company’s track record of navigating a patent cliff through new blockbuster launches.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
